HONG KONG, August 31, 2026 – (ACN Newswire) – Running Cash Flow Turns Positive for the First Time, with a Significantly Strengthened Capital Structure
On August 28, 2026, Micot Pharma (02335. HK), the very first openly noted peptide-focused ingenious drug business in Hong Kong, revealed its interim outcomes for the very first half of 2026.
Throughout the reporting duration, the Company taped research study and advancement expenditures of RMB128 million, representing a considerable year-on-year boost of 215.9%, showing a velocity in R&D financial investment. Net money produced from running activities reached RMB109 million, marking a turn-around from net operating money outflow in the matching duration of 2025.
A crucial factor to this shift was the commercialization collaboration for MT1013.
In February 2026, Micot Pharma participated in a special commercialization licensing contract with Everest Medicines for MT1013, the Company’s Core Product. Under the contract, Everest Medicines was given special commercialization rights for MT1013 in Greater China and the Asia-Pacific area omitting Japan for the treatment of secondary hyperparathyroidism (SHPT).
Micot Pharma got an in advance payment of RMB200 million and is qualified to get prospective regulative and business turning point payments of approximately RMB1.04 billion, along with tiered royalties based upon net item sales.
Since completion of June 2026, the Company’s money and monetary possessions amounted to roughly RMB1.227 billion, compared to RMB270 million at the end of 2025. Overall equity reached around RMB957 million, compared to net liabilities of around RMB960 million at the end of 2025. The Company’s tailoring ratio likewise decreased considerably from 389.6% to 25.2%.
For a clinical-stage biotechnology business, the fortifying of liquidity and capital structure supplies essential financial backing for the continued improvement of several scientific programs.
MT1013 Advances Through Phase III, with a Clearer Path Toward Commercialization
Beyond its monetary position, the crucial concern for the marketplace stays the development and scientific capacity of Micot Pharma’s pipeline.
MT1013 stays the Company’s most innovative property and the item closest to commercialization.
MT1013 is the world’s first-in-class, new-generation dual-targeting peptide drug being established for secondary hyperparathyroidism connected with persistent kidney illness (CKD-SHPT). The drug includes a pioneering double system of action–“CaSR agonist + OGP (Osteogenic Growth Peptide) mimetic.”
Unlike traditional methods that mostly concentrate on reducing parathyroid hormonal agent (PTH), MT1013 is created to manage PTH, calcium and phosphorus metabolic process while concurrently triggering osteogenic paths to promote bone development and repair work. This represents a possible healing shift from indirectly reducing bone resorption towards actively promoting bone development.
The Phase III scientific research study of MT1013 has actually finished client registration, and the Company anticipates to send a New Drug Application (NDA) in early 2027.
In a head-to-head medical research study versus the calcimimetic etelcalcetide, the composite target achievement rate for serum calcium, phosphorus, and iPTH in the MT1013 groups after 20– 27 weeks of treatment was 39.29% and 34.48%, respectively, around 2.2– 2.5 times that of etelcalcetide (15.63%).
In addition, the percentage of clients in the MT1013 groups attaining a decrease of more than 30% in undamaged parathyroid hormonal agent (iPTH) from standard reached 83.9%– 93.3%.
Scientific information from MT1013 have actually likewise been accepted as Late-Breaking Science by the American Society of Nephrology (ASN) Kidney Week.
Versus this background, Micot Pharma’s commercialization collaboration with Everest Medicines represents a crucial action in equating the scientific and clinical worth of MT1013 into prospective industrial worth.
Favorable Phase II Data for MT200605 Further Validate Its Potential as an Innovative Stroke Therapy
Quickly before the release of its interim outcomes, Micot Pharma revealed on August 26 that it had actually finished the Phase II medical trial of MT200605, its internally industrialized prospect for the treatment of severe ischemic stroke (AIS).
The research study was a multicenter, randomized, double-blind, placebo-controlled Phase II trial including 360 clients, who were randomized at a 1:1:1:1 ratio into 3 MT200605 dosage groups and a placebo group.
For the main effectiveness endpoint, the percentage of clients accomplishing a customized Rankin Scale (mRS) rating of 0– 1 in the high-dose MT200605 group was greater than that in the placebo group, with the chances ratio (OR) for practical healing enhancing by more than 100% versus placebo.
From a clinical-benefit viewpoint, the outcomes recommend that around one extra client might accomplish practical self-reliance for each 6 clients dealt with.
The signal is notable in the context of neuroprotection research study, a field in which equating biological systems into significant enhancements in practical results has actually traditionally been challenging.
For the secondary endpoints, enhancement in National Institutes of Health Stroke Scale (NIHSS) ratings in the high-dose group started to separate from placebo by Day 7. The instructions of enhancement followed the mRS results, with a more noticable distinction observed by Day 14, recommending much faster early neurological healing amongst clients getting high-dose MT200605.
Another distinguished observation included intense kidney injury (AKI).
MT200605 showed the prospective to lower the occurrence of AKI amongst clients with AIS in a dose-dependent way. In the high-dose group, the occurrence of AKI was more than 80% lower than that in the placebo group, showing prospective renal-protective advantages in addition to its neurological results.
A Differentiated BDNF/TrkB-Based Mechanism Supporting Potential Brain and Kidney Protection
Mechanistically, MT200605 is a little particle substance that functions as a tropomyosin receptor kinase B (TrkB) agonist with brain-derived neurotrophic aspect (BDNF)-like impacts.
By triggering TrkB, it regulates downstream signaling paths to secure the structure and function of brain neural tissues. In addition, it improves mitochondrial ATP synthesis and applies antioxidant results by scavenging oxygen totally free radicals.
This separated system might likewise add to the renal-protective signal observed in the Phase II trial.
MT200605 has actually gotten acknowledgment from both domestic and global clinical and regulative neighborhoods. The program has actually been chosen for China’s National Science and Technology Major Project for Innovative Drug Development. Its preclinical and Phase I scientific findings have actually likewise been accepted for oral discussion at the 18th World Stroke Congress.
In addition, the U.S. Food and Drug Administration approved Orphan Drug Designation to MT200605 for the treatment of Huntington’s illness in March 2026.
A Multi-Layered Pipeline Strengthens Micot Pharma’s Capacity for Sustained R&D Output
Beyond MT1013 and MT200605, Micot Pharma is developing a wider pipeline covering various phases of scientific advancement.
XTL6001, a GLP-1R/ GCGR/MasR triple agonist, has actually finished database lock for its Phase I medical trial. By including MasR into its system of action, XTL6001 is developed to extend its restorative capacity beyond weight management and metabolic policy towards kidney defense and anti-inflammatory and anti-fibrotic results.
Research study connecting to XTL6001 has actually been accepted for discussion at numerous significant worldwide clinical conferences, consisting of the American Diabetes Association (ADA) Scientific Sessions 2026, the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 and ASN Kidney Week 2026.
MT1002 continues to advance throughout signs consisting of anticoagulation throughout hemodialysis and intense ischemic stroke, additional broadening Micot Pharma’s advancement footprint in cardiovascular, cerebrovascular and kidney illness.
Getting In an Accelerated Validation Phase for R&D Outcomes
Taken together, the most essential takeaway from Micot Pharma’s 2026 interim outcomes is not whether a clinical-stage biotechnology business can accomplish near-term success.
Rather, 3 advancements are happening at the same time.
MT1013 has actually gone into the important late-stage medical advancement duration ahead of a possible NDA submission, while its commercialization collaboration with Everest Medicines has actually developed a clearer path towards commercialization.
Second, the Phase II outcomes of MT200605 have actually supplied more medical proof supporting the healing capacity of its separated system in severe ischemic stroke.
Third, follows the Company’s Hong Kong listing, together with the in advance payment gotten under the MT1013 commercialization arrangement, have considerably strengthened Micot Pharma’s liquidity and capital structure, offering higher monetary versatility to advance its medical pipeline.
For financiers and market observers, these advancements might represent the main style through which Micot Pharma’s very first interim outcomes following its Hong Kong listing must be comprehended: the Company is moving from a phase controlled by R&D financial investment towards one in which medical development, external collaborations and pipeline worth are significantly being confirmed through concrete turning points.
Subject: Press release summary